Skip to content
Mexitil, Namuscla(mexiletine)
Mexitil, Namuscla (mexiletine) is a small molecule pharmaceutical. Mexiletine was first approved as Mexitil on 1985-12-30. It is used to treat cardiac arrhythmias, diabetic neuropathies, ventricular fibrillation, and ventricular premature complexes in the USA. It has been approved in Europe to treat myotonic disorders. The pharmaceutical is active against sodium channel protein type 4 subunit alpha.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
nervous system diseasesD009422
cardiovascular diseasesD002318
endocrine system diseasesD004700
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mexiletine hydrochloride
Tradename
Company
Number
Date
Products
MEXITILBoehringer IngelheimN-018873 DISCN1985-12-30
3 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
mexiletine hydrochlorideANDA2023-06-16
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
cardiac arrhythmiasEFO_0004269D001145I49.9
diabetic neuropathiesEFO_1000783D003929—
ventricular fibrillationEFO_0004287D014693I49.01
ventricular premature complexes—D018879I49.3
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C01: Cardiac therapy drugs
— C01B: Antiarrhythmics, class i and iii
— C01BB: Antiarrhythmics, class ib
— C01BB02: Mexiletine
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMEXILETINE
INNmexiletine
Description
Mexiletine is an aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol. It has a role as an anti-arrhythmia drug. It is an aromatic ether and a primary amino compound.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1cccc(C)c1OCC(C)N
Identifiers
PDB—
CAS-ID31828-71-4
RxCUI—
ChEMBL IDCHEMBL558
ChEBI ID6916
PubChem CID4178
DrugBankDB00379
UNII ID1U511HHV4Z (ChemIDplus, GSRS)
Target
Agency Approved
SCN4A
SCN4A
Organism
Homo sapiens
Gene name
SCN4A
Gene synonyms
NCBI Gene ID
6329
Protein name
sodium channel protein type 4 subunit alpha
Protein synonyms
CTC-264K15.6, skeletal muscle sodium channel alpha subunit, skeletal muscle voltage-dependent sodium channel type IV alpha subunit, SkM1, Sodium channel protein skeletal muscle subunit alpha, Sodium channel protein type IV subunit alpha, sodium channel, voltage-gated, type IV, alpha subunit, Voltage-gated sodium channel subunit alpha Nav1.4
Uniprot ID
Q7Z6B1
Mouse ortholog
Scn4a (110880)
sodium channel protein type 4 subunit alpha (Q9ER60)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 3,224 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details